Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Incoming news?

$Mainz Biomed (MYNZ.US)$  rumors of expected news today on stocktwits. NFA
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
Translate
Report
9552 Views
Comment
Sign in to post a comment
  • Captain T OP :

    07/25/2024 - 08:01 AM
    BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in early detection of cancer, today announced significant improvements to its ColoAlert product, currently being commercialized across Europe and in select international markets. These updates aim to enhance customer satisfaction and streamline lab operations.


    ColoAlert is a highly efficacious and easy-to-use, at-home detection test for colorectal cancer (CRC). The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemical test (FIT). It is designed to detect tumor DNA and CRC cases in their earliest stages.

    To increase screening/lab efficiency, Mainz Biomed has introduced a novel DNA stabilizing buffer capable of accommodating varying sample volumes. This breakthrough addresses a common issue in the industry where samples are often either underfilled or overfilled, rendering them unsuitable for laboratory analysis. Consequently, patients frequently have to repeat their screening test. The new proprietary buffer used in ColoAlert significantly reduces the necessity for additional sample submissions, thereby reducing the time for the patients to obtain their results. This enhancement has enabled ColoAlert to achieve the industry's lowest retesting rates, ensuring that screening outcomes are delivered within just 2 - 3 days upon arrival at the laboratory.

32Followers
47Following
308Visitors
Follow